Prediabetes diagnosis and treatment: A review.

Prediabetes is an intermediate state of hyperglycemia with glycemic parameters above normal but below the diabetes threshold. While, the diagnostic criteria of prediabetes are not uniform across various international professional organizations, it remains a state of high risk for developing diabetes with yearly conversion rate of 5%-10%. Observational evidence suggests as association between prediabetes and complications of diabetes such early nephropathy, small fiber neuropathy, early retinopathy and risk of macrovascular disease. Several studies have shown efficacy of lifestyle interventions with regards to diabetes prevention with a relative risk reduction of 40%-70% in adults with prediabetes. While there is increasing evidence to prove the efficacy of pharmacotherapy in prevention of diabetes in adults with prediabetes, pharmaceutical treatment options other than metformin are associated with adverse effects that limit their use for prediabetes. There are no reports of systematic evaluation of health outcomes related to prediabetes in children. The effects of pharmacotherapy of prediabetes on growth and pubertal development in children remains unknown. Secondary intervention with pharmacotherapy with metformin is advocated for high-risk individuals but criteria for such consideration benefit of early intervention, long term cost effectiveness of such interventions and the end point of therapy remain unclear. Pharmacotherapy must be used with caution in children with prediabetes. Prediabetes is a condition defined as having blood glucose levels above normal but below the defined threshold of diabetes. It is considered to be an at risk state, with high chances of developing diabetes. While, prediabetes is commonly an asymptomatic condition, there is always presence of prediabetes before the onset of diabetes. The elevation of blood sugar is a continuum and hence prediabetes can not be considered an entirely benign condition. This aim of this review is to describe the challenges associated with diagnosis of prediabetes, the possible adverse medical outcomes associated with prediabetes and the treatment options and rationale for their use in context of prediabetes.

[1]  P. Metcalf,et al.  Microalbuminuria in a Middle-Aged Workforce: Effect of hyperglycemia and ethnicity , 1993, Diabetes Care.

[2]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[3]  N. Wareham,et al.  Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: The Ely study 1990–2000 , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[4]  J. Shaw,et al.  Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) , 2007, Circulation.

[5]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[6]  R. Kahn,et al.  A Step Backward—or Is it Forward? The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the American Diabetes Association. , 2008, Diabetes Care.

[7]  M. McDonagh,et al.  Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. , 2014, JAMA pediatrics.

[8]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[9]  B. Balkau,et al.  The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group , 2006, Diabetologia.

[10]  W. Post,et al.  Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis). , 2011, Journal of the American College of Cardiology.

[11]  Paul Mitchell,et al.  Retinal Arteriolar Narrowing Predicts Incidence of Diabetes , 2008, Diabetes.

[12]  A. Gosmanov,et al.  Low Positive Predictive Value of Hemoglobin A1c for Diagnosis of Prediabetes in Clinical Practice , 2014, The American journal of the medical sciences.

[13]  B. Billah,et al.  Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials , 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[14]  T. Wong,et al.  Retinal Vascular Changes in Pre-Diabetes and Prehypertension , 2007, Diabetes Care.

[15]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[16]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[17]  R. Heethaar,et al.  Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study , 2000, Diabetologia.

[18]  R. Hanson,et al.  Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. , 2000, Diabetes care.

[19]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[20]  F. Nuttall.  Evidence for Independent Heritability of the Glycation Gap (Glycosylation Gap) Fraction of HbA1c in Nondiabetic Twins , 2007, Diabetes Care.

[21]  S. Tripp,et al.  Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy , 2001, Neurology.

[22]  N. Powe,et al.  Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[23]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[24]  S. Kashyap,et al.  Metabolic syndrome and kidney disease: a systematic review and meta-analysis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[25]  C. Bouchard,et al.  Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.

[26]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[27]  Ambady Ramachandran,et al.  Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2) , 2009, Diabetologia.

[28]  A. Rissanen,et al.  Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. , 2000, Archives of internal medicine.

[29]  C. Sumner,et al.  The spectrum of neuropathy in diabetes and impaired glucose tolerance , 2003, Neurology.

[30]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[31]  J. Singleton,et al.  The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. , 2004, Archives of internal medicine.

[32]  J. Lindström,et al.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study , 2006, The Lancet.

[33]  K. Kosaka,et al.  HbA1c 5·7–6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study , 2011, The Lancet.

[34]  S. Haffner,et al.  Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? , 2002, Annals of Internal Medicine.

[35]  J. Rosenstock,et al.  Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes , 2010, Diabetes Care.

[36]  Rayaz A. Malik,et al.  Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments , 2010, Diabetes Care.

[37]  K. Shimamoto,et al.  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance , 2009, The Lancet.

[38]  D. Levy,et al.  Glycemic status and development of kidney disease: the Framingham Heart Study. , 2005, Diabetes care.

[39]  J. Zhang,et al.  Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study , 2011, Diabetologia.

[40]  M. Bromberg,et al.  Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. , 2001, Diabetes care.

[41]  U. Smith,et al.  Pioglitazone: mechanism of action. , 2001, International journal of clinical practice. Supplement.

[42]  P. Raina,et al.  Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review , 2007, Clinical chemistry and laboratory medicine.

[43]  H. Bischoff.  The mechanism of alpha-glucosidase inhibition in the management of diabetes. , 1995, Clinical and investigative medicine. Medecine clinique et experimentale.

[44]  Bo Zhang,et al.  The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study , 2008, The Lancet.

[45]  W. Garvey,et al.  Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. , 2014, Metabolic syndrome and related disorders.

[46]  L. Chambless,et al.  Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. , 2005, Diabetes care.

[47]  Martin J Shipley,et al.  Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. , 2006, Diabetes care.

[48]  C. Snehalatha,et al.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) , 2006, Diabetologia.

[49]  Devjit Tripathy,et al.  Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.

[50]  S. Yusuf,et al.  Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose , 2008, Diabetes Care.

[51]  G. Ning,et al.  Retinol-binding protein 4 is associated with impaired glucose regulation and microalbuminuria in a Chinese population , 2009, Diabetologia.

[52]  G. Nijpels,et al.  Relationship Between A1C and Glucose Levels in the General Dutch Population , 2009, Diabetes Care.

[53]  Chih-Hsing Wu,et al.  Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. , 2007, The Journal of clinical endocrinology and metabolism.

[54]  Z. T. Bloomgarden,et al.  The proposed terminology ‘A1c-derived average glucose’ is inherently imprecise and should not be adopted , 2008, Diabetologia.

[55]  M. Godwin,et al.  Treating prediabetes with metformin: systematic review and meta-analysis. , 2009, Canadian family physician Medecin de famille canadien.

[56]  S. Efendić,et al.  Retinal microangiopathy and pigment epithelial lesions in subjects with normal, borderline, and decreased oral glucose tolerance. , 1985, The British journal of ophthalmology.

[57]  Christine M. Hoehner,et al.  Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. , 2002, Journal of the American Society of Nephrology : JASN.

[58]  R. Jorde,et al.  Idiopathic polyneuropathy and impaired glucose metabolism in a Norwegian patient series , 2008, European journal of neurology.

[59]  Benn Smith,et al.  Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. , 2006, Archives of neurology.

[60]  E. Barinas-Mitchell,et al.  Reproducibility of the oral glucose tolerance test in overweight children. , 2008, The Journal of clinical endocrinology and metabolism.

[61]  J. Shaw,et al.  Longitudinal Association of Glucose Metabolism With Retinopathy , 2008, Diabetes Care.

[62]  K. Eriksson,et al.  No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise , 1998, Diabetologia.

[63]  B. Zinman,et al.  Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study , 2010, The Lancet.

[64]  Jagmeet P. Singh,et al.  Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). , 2000, The American journal of cardiology.

[65]  S. Tesfaye,et al.  Noninvasive Evaluation of Neural Impairment in Subjects With Impaired Glucose Tolerance , 2009, Diabetes Care.

[66]  G. Dohm,et al.  Is type II diabetes mellitus (NIDDM) a surgical disease? , 1992, Annals of surgery.

[67]  L. Coupal,et al.  The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. , 2006, Archives of internal medicine.